From Generics to Global Leadership: State-Level Policies and India’s Pharmaceutical Transformation (2010–2025)

Abstract

Between 2010 and 2025, India’s pharmaceutical industry underwent a striking transformation. What was once seen primarily as a cost‑competitive generics hub, matured into a global supplier of vaccines, complex generics, APIs, and biologics. National schemes such as the PLI program, Jan Aushadhi, and regulatory reforms provided the broad policy framework, but state governments played a decisive yet often overlooked role in shaping industrial outcomes.

This paper compares the strategies of seven reform‑oriented states- Gujarat, Telangana, Andhra Pradesh, Tamil Nadu, Uttar Pradesh, Karnataka, and Kerala, alongside legacy clusters in Maharashtra, Uttarakhand, Himachal Pradesh, Sikkim, Assam, and Goa. Using a mixed qualitative framework that integrates policy review, ecosystem assessment, and outcome mapping, it evaluates how fiscal incentives, infrastructure, innovation ecosystems, and governance mechanisms translated into manufacturing scale, export strength, and regulatory credibility.

The findings suggest that states which emphasized regulatory continuity, infrastructure execution, and institutional coordination achieved more durable results than those relying mainly on fiscal incentives. By highlighting state‑level diversity and execution capacity, the study proposes a framework for designing pharmaceutical strategies that are context‑sensitive, outcome‑oriented, and aligned with long‑term sustainability. Unlike earlier work that focused narrowly on national schemes or individual clusters, this review provides a longitudinal, cross‑state perspective spanning 15 years.

Keywords: Pharmaceutical policy, Innovation Ecosystems, API Manufacturing Revival, Environmental Regulation, Fiscal Incentives Pharma, Bulk Drug Parks